Hi, thank you for the opportunity. The first one on the Nacharam plant, so we are seeing that the impact is around INR55 crore, right?
Can you hear me now? Is it better?
Questions across 3 calls
Kunal Damesha
Macquarie
Cohance Lifesciences Limited
Syngene International Limited
Hi, thank you for the opportunity. The first question is on the impact on the biologic product which was announced in this quarter and seems an impact in previous quarter as well, but a s the year goes by, how do we expect the impact of this in Q4 and how are we getting from the F Y27 prospect, demand comes back here, are there other drivers which basically help us grow from within our CMO business? And also, if you could provide a broad split between the CRO and CMO business this quarter, that would be helpful?
Sorry, I just missed a moment in between. You expect the impact to continue in the next year or are you just guiding for the next quarter as of now?
Global Health Limited
Thank you for the opportunity. On this retrofitting of a floor for medical oncology, I'm sure rationale would be demand for that service. But is there any meaningful difference in terms of profitability, ret urn on investment that we would be doing here versus some of the other specialties?
Yes, on the business side, you know, how things operate here, but, some of you on the financial side, how kind of, you know, it helps us because I believe one of our peers has a very strong oncology contribution, you know, and that's been growing really fast as well as I think it also has a favorable profitability profile. So, is that the similar kind of trend that you are also witnessing?